News

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

Survey and RESONATE trial data suggest a -0.22-point drop in the Combined Symptom and Medication Score signal meaningful benefit.

A study links the use of nasal corticosteroids to a greater risk of SARS-CoV-2 infection in adults, but not in children.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

The global burden of CKD attributable to high BMI has shown a consistent upward trend from 1990 to 2021, with projections further increases by 2050.

This new monoclonal antibody has achieved a statistically significant improvement in time to treatment failure, indicating a potential to revolutionize ITP.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

This August 2025 News Update spotlights Ugonabo’s career journey, her award and its story, and the growing importance of tailored dermatologic care for diverse skin tones.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

After overcoming 2 FDA rejections, PharmaTher secures approval for ketamine (KETARX) in surgical pain.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

An audio recap of the top 5 stories in healthcare news from the week of 08/03-08/09.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

Stay updated with the latest healthcare breakthroughs, including an FDA approval and new clinical trial data, in this week's essential news roundup.

Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.

Both trials indicated lasting visual improvements in patients treated with Ixo-vec who had previously received anti-VEGF injections.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.

Cafraglutide was effective with less frequent dosing than currently available medications that target GLP-1.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

Findings from the IBS in America Survey suggest IBS symptoms disrupt patients’ productivity and personal activities 19 days each month.

An interim report from the ongoing trial shows few adverse events resulting from 60 weeks of treatment with the combined AAV vector/dual-transgene cassette.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

The new, bioerodible intravitreal implant, which periodically releases the tyrose kinase inhibitor vorolanib, may be capable of reducing treatment burden for at least 6 months.